FacebookTwitterGoogle+RedditEmail

FDA Commissioner Hamburg Appointed WHO Deputy?

Many had high hopes for the FDA when Margaret Hamburg was confirmed as Commissioner in 2009 because of her public health background. But she swiftly moved to loosen conflict of interest rules governing those who can serve on FDA expert advisory panels, claiming it was too hard to find experts without Pharma financial links.

Her move followed a Philadelphia Inquirer reporter’s revelations that child psychiatrist Jorge Armenteros, a paid consultant to AstraZeneca, was on an FDA committee voting on–any guesses?–the AstraZeneca drug Seroquel.

Last month, more questions about embedded conflicts of interest at the FDA were raised when Commissioner Hamburg appointed Robert Califf, M.D., chancellor of clinical and translational research at Duke University, as the next FDA Deputy Commissioner for Medical Products and Tobacco despite a thicket of conflicts of interest. It was one of her last official acts before announcing her resignation last week.

A disclosure statement on the website of Duke Clinical Research Institute says “Robert M. Califf, MD, reports receiving research grant support from Novartis Pharmaceuticals, Johnson & Johnson/Scios, Lilly, Merck, and Schering Plough, and consulting fees from Annenberg, Aterovax, Bayer/Ortho McNeil, BMS, Boehringer Ingelheim, GSK, WebMd/theheart.org, Johnson and ohnson/Scios, Kowa Research Institute, McKinsey & Company, Medtronic, Merck, Novartis Pharmaceuticals, Sanofi Aventis, and Schering Plough, and has an equity position with NITROX, LLC.”

In disclosure information for a 2013 article in Circulation, Dr. Califf’s also lists financial links to Gambro, Regeneron, Gilead, AstraZeneca, Roche, others companies and equity positions in four medical companies. The medical website Medscape discloses that Dr. Califf “served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech” as well as for Medscape LLC/theheart.org. Portola Pharmaceuticals says Dr. Califf served on the Board of Directors until he was appointed FDA Deputy Commissioner for Medical Products and Tobacco.

Appearing on PBS with Susan Dentzer after Vioxx was withdrawn because of its links to thousands of heart attacks and stroke, Dr. Califf said, “Merck played by the rules from everything that I’ve seen.” He also said, “many of us consult with the pharmaceutical industry, which I think is a very good thing. They need ideas and then the decision about what they do is really up to the person who is funding the study.” What?

This is not the first time Dr. Califf’s extreme Pharma links have not blocked him from consideration for a top government post. He was up for Dr. Hamburg’s job itself, reported Reutersalong with three others. At the time, some medical voices asked how someone who helps drug companies market their products could possibly be considered as the nation’s chief watchdog over unsafe medications.

Industry conflicts at the FDA cost lives. Recently Senators Joe Manchin (D-W.Va.) and David Vitter (R-La.) questioned whether the FDA’s approval last year of the synthetic opioid Zohydro stemmed from pay-to-play meetings with Big Pharma who allegedly shelled out thousands to meet with regulators. Big Pharma’s hand in the opioid epidemic which causes 17,000 overdose deaths a year in the U.S. is well documented and egregious.

Commissioner Hamburg’s appointment of Dr. Califf amounts to a sad legacy. It also suggests the FDA is no longer even making a pretense at policing industry/government conflicts of interest.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Weekend Edition
April 20, 2018
Friday - Sunday
Paul Street
Ruling Class Operatives Say the Darndest Things: On Devils Known and Not
Conn Hallinan
The Great Game Comes to Syria
Jeffrey St. Clair
Roaming Charges: Mother of War
Andrew Levine
“How Come?” Questions
Doug Noble
A Tale of Two Atrocities: Douma and Gaza
Kenneth Surin
The Blight of Ukania
Howard Lisnoff
How James Comey Became the Strange New Hero of the Liberals
William Blum
Anti-Empire Report: Unseen Persons
Lawrence Davidson
Missiles Over Damascus
Patrick Cockburn
The Plight of the Yazidi of Afrin
Pete Dolack
Fooled Again? Trump Trade Policy Elevates Corporate Power
Stan Cox
For Climate Mobilization, Look to 1960s Vietnam Before Turning to 1940s America
William Hawes
Global Weirding
Dan Glazebrook
World War is Still in the Cards
Nick Pemberton
In Defense of Cardi B: Beyond Bourgeois PC Culture
Ishmael Reed
Hollywood’s Last Days?
Peter Certo
There Was Nothing Humanitarian About Our Strikes on Syria
Dean Baker
China’s “Currency Devaluation Game”
Ann Garrison
Why Don’t We All Vote to Commit International Crimes?
LEJ Rachell
The Baddest Black Power Artist You Never Heard Of
Lawrence Ware
All Hell Broke Out in Oklahoma
Franklin Lamb
Tehran’s Syria: Lebanon Colonization Project is Collapsing
Donny Swanson
Janus v. AFSCME: What’s It All About?
Will Podmore
Brexit and the Windrush Britons
Brian Saady
Boehner’s Marijuana Lobbying is Symptomatic of Special-Interest Problem
Julian Vigo
Google’s Delisting and Censorship of Information
Patrick Walker
Political Dynamite: Poor People’s Campaign and the Movement for a People’s Party
Fred Gardner
Medical Board to MDs: Emphasize Dangers of Marijuana
Rob Seimetz
We Must Stand In Solidarity With Eric Reid
Missy Comley Beattie
Remembering Barbara Bush
Wim Laven
Teaching Peace in a Time of Hate
Thomas Knapp
Freedom is Winning in the Encryption Arms Race
Mir Alikhan
There Won’t be Peace in Afghanistan Until There’s Peace in Kashmir
Robert Koehler
Playing War in Syria
Tamara Pearson
US Shootings: Gun Industry Killing More People Overseas
John Feffer
Trump’s Trade War is About Trump Not China
Morris Pearl
Why the Census Shouldn’t Ask About Citizenship
Ralph Nader
Bill Curry on the Move against Public Corruption
Josh Hoxie
Five Tax Myths Debunked
Leslie Mullin
Democratic Space in Adverse Times: Milestone at Haiti’s University of the Aristide Foundation
Louis Proyect
Syria and Neo-McCarthyism
Dean Baker
Finance 202 Meets Economics 101
Abel Cohen
Forget Gun Control, Try Bullet Control
Robert Fantina
“Damascus Time:” An Iranian Movie
David Yearsley
Bach and Taxes
FacebookTwitterGoogle+RedditEmail